Q3 2024 EPS Estimates for Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Raised by Analyst

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) – Equities researchers at Roth Capital increased their Q3 2024 earnings estimates for shares of Cyclacel Pharmaceuticals in a research note issued on Wednesday, August 14th. Roth Capital analyst J. Aschoff now anticipates that the biotechnology company will earn ($0.54) per share for the quarter, up from their prior forecast of ($0.62). The consensus estimate for Cyclacel Pharmaceuticals’ current full-year earnings is ($4.93) per share. Roth Capital also issued estimates for Cyclacel Pharmaceuticals’ Q4 2024 earnings at ($0.40) EPS, FY2024 earnings at ($2.29) EPS, FY2025 earnings at ($1.56) EPS, FY2026 earnings at ($1.59) EPS, FY2027 earnings at $4.26 EPS and FY2028 earnings at $6.67 EPS.

A number of other brokerages have also recently weighed in on CYCC. StockNews.com cut Cyclacel Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, June 27th. Roth Mkm decreased their price target on shares of Cyclacel Pharmaceuticals from $21.00 to $11.00 and set a “buy” rating for the company in a research report on Friday, May 3rd.

Cyclacel Pharmaceuticals Stock Down 3.8 %

Cyclacel Pharmaceuticals stock opened at $1.27 on Monday. Cyclacel Pharmaceuticals has a twelve month low of $1.22 and a twelve month high of $11.34. The business has a fifty day moving average of $1.62 and a two-hundred day moving average of $2.04. The firm has a market cap of $1.85 million, a P/E ratio of -0.06 and a beta of 0.59.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last posted its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.11. Cyclacel Pharmaceuticals had a negative return on equity of 1,953.78% and a negative net margin of 21,963.75%. During the same quarter in the prior year, the business posted ($6.60) EPS.

Hedge Funds Weigh In On Cyclacel Pharmaceuticals

An institutional investor recently bought a new position in Cyclacel Pharmaceuticals stock. Armistice Capital LLC purchased a new position in shares of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 134,000 shares of the biotechnology company’s stock, valued at approximately $217,000. Armistice Capital LLC owned 9.18% of Cyclacel Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. 23.58% of the stock is owned by hedge funds and other institutional investors.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.